Precipitins to mannan and cytoplasmic antigens of three Candida species were determined in an unselected series of 289 non-pregnant women. Precipitins were present in 20% of sera of women with vaginal candidiasis, in 23% of women harbouring yeasts in the vagina without clinical signs of infection, and in 21% of women harbouring yeasts in sites other than the vagina. Of the 47 patients who react...

Data sources Randomised controlled trials (RCTs) published in any language were identified by searching the Cochrane Controlled Trials Register (CENTRAL/CCTR), the Cochrane Collaboration Sexually Transmitted Disease Group Specialised Register of Controlled Trials, EMBASE/Excerpta Medica (1980 to January 2000), and Medline (January 1985 to May 2000). Reference lists of each trial were reviewed, ...

Vulvovaginal candidiasis (VVC) is an extremely common cause of vaginal symptoms in women. Multiple antifungal products are available by either the oral or vaginal route, although no new drugs have become available for two decades. Given the therapeutic equivalence of the antimycotic agents and their routes of administration, the specific drug and formulation selected is entirely arbitrary in re...

BACKGROUND During reproductive age 75% of women experience at least one episode of vulvovaginal candidiasis, approximately 6% to 55% of healthy women are asymptomatic carriers. In Mexico there are no current data of the frequency of vaginal colonization by Candida in the general population. OBJECTIVE To determine the frequency of the colonization by Candida species in asymptomatic women. MA...

Vulvo-vaginal candidiasis (VVC) is a common infection among women. 5-8% of women with acute infection experience recurrent vulvo-vaginal candidiasis (RVVC). There is currently no gold standard treatment for RVVC. Although antifungal agents such as imidazoles have been successfully used as first-line treatment for acute VVC, the effectiveness of these medications is limited for RVVC, and various...